About metabolIQ
metabolIQ is a Healthcare company based in Canada founded in 2022. It operates as a developer of cell culture medium for pharmaceutical screening and personalized medicine. metabolIQ offers products and services including metabolIQ Technology. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Cell Culture. Its competitors include Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio and 3 more; 3 of its 8 listed competitors have raised funding.
Company details
metabolIQ was founded in 2022 in Canada within the biotechnology sector. Cell culture media are developed for applications in pharmaceutical screening and personalized medicine. Induced pluripotent stem cell-derived cardiomyocytes are provided to support physiological maturation in purified monolayer and organoid systems. These resources are utilized across scientific research and industrial processes.
- Headquarters Canada
- SectorsHealthcare
- Website metaboliq.ca
Products & Services of metabolIQ
metabolIQ offers a comprehensive portfolio of products and services, including metabolIQ Technology.
Provides platform for cardiac science from bench research to bedside use.
Competitors of metabolIQ
metabolIQ has 8 listed competitors in our database, 3 of them funded. They include Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| multus.bio | 2019 | London, United Kingdom | $9.3M | 8 | Provider of lab-grown meat alternatives | |
| metatissue.com | 2018 | Ilhavo, Portugal | – | – | Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications | |
| nu-tekbiosciences.com | 2008 | Minnetonka, United States | – | – | Develops innovative animal-free peptones and cell culture media for pharmaceutical use. | |
| kohjin-bio.jp | 1981 | Sakado, Japan | – | – | Tissue culture media provided for regenerative medicine and immunotherapy research. | |
| sarvoshadhi.com | 2017 | Kolhapur, India | – | – | Customized cell culture media for biotechnology are developed. | |
| onkologic.com | 2021 | Farmington, United States | $305,000 | – | NK cell culture media is developed for cancer cell therapies. | |
| alt-biotech.com | 2023 | Evry Courcouronnes, France | – | – | Delivers comprehensive cell-culture solutions for producing non-therapeutic recombinant proteins. | |
| cet.bio | 2000 | Coralville, United States | $45,000 | – | Cell lines and stem cell products are supplied to researchers. |
Detailed competitors of metabolIQ
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as metabolIQ (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about metabolIQ
metabolIQ was founded in 2022.
metabolIQ is headquartered in Canada.
metabolIQ was founded in 2022 in Canada within the biotechnology sector. Cell culture media are developed for applications in pharmaceutical screening and personalized medicine. Induced pluripotent stem cell-derived cardiomyocytes are provided to support physiological maturation in purified monolayer and organoid systems. These resources are utilized across scientific research and industrial processes.
metabolIQ's top competitors include Multus, Onkologic and Cellular Engineering Technologies.
metabolIQ offers metabolIQ Technology.